Orthofix Medical (OFIX) EBITDA (2010 - 2026)

Orthofix Medical's EBITDA history runs 17 years deep, the most recent figure standing at $17.7 million for Q1 2026.

• Quarterly EBITDA fell 9.02% year-over-year to $17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.1 million (up 3.53% YoY) and the FY2025 annual result came in at $118.9 million, up 6.11% from the prior year.
• EBITDA was $17.7 million for Q1 2026 at Orthofix Medical, down from $37.9 million in the prior quarter.
• Across five years, EBITDA topped out at $37.9 million in Q4 2025 and bottomed at $3.2 million in Q1 2023.
• A 5-year average of $23.3 million and a median of $23.1 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA tumbled 54.93% — and 2024, when it soared 474.22%.
• Orthofix Medical's EBITDA stood at $35.2 million in 2022, then fell by 8.06% to $32.3 million in 2023, then increased by 10.32% to $35.7 million in 2024, then climbed by 6.26% to $37.9 million in 2025, then sank by 53.23% to $17.7 million in 2026.
• Business Quant data shows OFIX's EBITDA at $17.7 million in Q1 2026, $37.9 million in Q4 2025, and $32.5 million in Q3 2025.